Abstract
Mefenamic acid is a nonsteroidal anti-inflammatory drug and a prostaglandin inhibitor useful in the treatment of patients with primary dysmenorrhea and fenoverine is a calcium modulator prescribed as an antispasmodic. The goal of this study was to compare the effectiveness of fenoverine and mefenamic in the treatment of women having primary dysmenorrhea with pain interfering with daily activities. An open-label prospective randomized crossover study was conducted in 51 Mexican women aged 18 years and older who had primary dysmenorrhea regular menstrual cycles and pain scores of 5 or higher on an analog visual scale (AVS). The study was conducted over 3 menstrual cycles as follows: (A) At cycle 1 (baseline cycle) pain severity was measured on the first day of menstruation and the 4 following days accompanying symptoms were noted as well as pain interference with daily activities and an analgesic was administered; (B) at cycle 2 on the 5 corresponding days the women were randomly assigned to take 200mg of fenoverine (Spasmopriv; Senosiain Laboratories Mexico) every 12h or 500mg of mefenamic acid (Namifen; Novag Infancia Laboratiries Mexico) every 8h; and (C) at cycle 3 the participants switched treatments. (excerpt)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call